Kaimin Guo
Research Subjects
Kaimin Guo has a total of 200 co-authors. Here are the top co-authors by number of shared publications:
- Yunhui Hu
Tianjin Tasly Digital Intelligence Chinese Medicine Technology Co., Ltd., Tianjin, China
2 shared publications Alexis Fergis
1 shared publication- Alexis R. Demonbreun
Center for Genetic Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
1 shared publication Allison M. Tomasino
1 shared publication- Amedeo Columbano
Department of Biomedical Sciences, Unit of Oncology and Molecular Pathology, University of Cagliari, Cagliari, Italy
1 shared publication - Ammar Qureshi
Department of Gastroenterology and Hepatology, University of California - Riverside School of Medicine, Rialto, CA, USA
1 shared publication
Latest Publications
- Open Access
- 28 September 2024
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (10) , 1295
Identification of Key Immune and Cell Cycle Modules and Prognostic Genes for Glioma Patients through Transcriptome Analysis
Background: Gliomas, the most prevalent type of primary brain tumor, stand out as one of the most aggressive and lethal types of human cancer. Methods & Results: To uncover potential prognostic markers, we employed the weighted correlation network analysis (WGCNA) on the Chinese Glioma Genome Atlas (CGGA) 693 dataset to reveal four modules significantly associated with glioma clinical traits, primarily involved in immune function, cell cycle regulation, and ribosome biogenesis. Using the least absolute shrinkage and selection operator (LASSO) regression algorithm, we identified 11 key genes and developed a prognostic risk score model, which exhibits precise prognostic prediction in the CGGA 325 dataset. More importantly, we also validated the model in 12 glioma patients with overall survival (OS) ranging from 4 to 132 months using mRNA sequencing and immunohistochemical analysis. The analysis of immune infiltration revealed that patients with high-risk scores exhibit a heightened immune infiltration, particularly immune suppression cells, along with increased expression of immune checkpoints. Furthermore, we explored potentially effective drugs targeting 11 key genes for gliomas using the library of integrated network-based cellular signatures (LINCS) L1000 database, identifying that in vitro, both torin-1 and clofarabine exhibit promising anti-glioma activity and inhibitory effect on the cell cycle, a significant pathway enriched in the identified glioma modules. Conclusions: In conclusion, our study provides valuable insights into molecular mechanisms and identifying potential therapeutic targets for gliomas.
- 28 September 2024
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (10) , 1295
Open AccessIdentification of Key Immune and Cell Cycle Modules and Prognostic Genes for Glioma Patients through Transcriptome Analysis
Background: Gliomas, the most prevalent type of primary brain tumor, stand out as one of the most aggressive and lethal types of human cancer. Methods & Results: To uncover potential prognostic markers, we employed the weighted correlation network analysis (WGCNA) on the Chinese Glioma Genome Atlas (CGGA) 693 dataset to reveal four modules significantly associated with glioma clinical traits, primarily involved in immune function, cell cycle regulation, and ribosome biogenesis. Using the least absolute shrinkage and selection operator (LASSO) regression algorithm, we identified 11 key genes and developed a prognostic risk score model, which exhibits precise prognostic prediction in the CGGA 325 dataset. More importantly, we also validated the model in 12 glioma patients with overall survival (OS) ranging from 4 to 132 months using mRNA sequencing and immunohistochemical analysis. The analysis of immune infiltration revealed that patients with high-risk scores exhibit a heightened immune infiltration, particularly immune suppression cells, along with increased expression of immune checkpoints. Furthermore, we explored potentially effective drugs targeting 11 key genes for gliomas using the library of integrated network-based cellular signatures (LINCS) L1000 database, identifying that in vitro, both torin-1 and clofarabine exhibit promising anti-glioma activity and inhibitory effect on the cell cycle, a significant pathway enriched in the identified glioma modules. Conclusions: In conclusion, our study provides valuable insights into molecular mechanisms and identifying potential therapeutic targets for gliomas.
- Open Access
- 20 July 2022
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2022 (1) , 1718353
DRDB: A Machine Learning Platform to Predict Chemical‐Protein Interactions towards Diabetic Retinopathy
Diabetic retinopathy (DR), a diabetic microangiopathy caused by diabetes, affects approximately 93 million people, worldwide. However, the drugs used to treat DR have limited efficacy and the variety of side effects. This is possibly because the complicated pathogenesis of DR is associated with multiple proteins. In this work, we attempted to identify potential drugs against DR‐associated proteins and predict potential targets for drugs using in silico prediction of chemical‐protein interactions (CPI) based on multitarget quantitative structure‐activity relationship (mt‐QSAR) method. Therefore, we developed 128 binary classifiers to predict the CPI for 15 DR targets using random forest (RF), k‐nearest neighbours (KNN), support vector machine (SVM), and neural network (NN) algorithms with MACCS, extended connectivity fingerprints (ECFP6) fingerprints, and protein descriptors. In order to facilitate discovery of the novel drugs and target identification using the 128 binary classifiers, a free web server (DRDB) was developed. Compound Danshen Dripping Pills (CDDP), composed of Salvia miltiorrhiza, Panax notoginseng, and borneol, is commonly used in the treatment of cardiovascular diseases. To explore the applicability of DRDB, the potential CPIs of CDDP in treatment of DR were investigated based on DRDB. In vitro experimental validation demonstrated that cryptotanshinone and protocatechuic acid, two key components of CDDP, are capable of targeting ICAM‐1 which is one of the key target of DR. We hope that this work can facilitate development of more effective clinical strategies for the treatment of DR.
- 20 July 2022
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2022 (1) , 1718353
Open AccessDRDB: A Machine Learning Platform to Predict Chemical‐Protein Interactions towards Diabetic Retinopathy
Diabetic retinopathy (DR), a diabetic microangiopathy caused by diabetes, affects approximately 93 million people, worldwide. However, the drugs used to treat DR have limited efficacy and the variety of side effects. This is possibly because the complicated pathogenesis of DR is associated with multiple proteins. In this work, we attempted to identify potential drugs against DR‐associated proteins and predict potential targets for drugs using in silico prediction of chemical‐protein interactions (CPI) based on multitarget quantitative structure‐activity relationship (mt‐QSAR) method. Therefore, we developed 128 binary classifiers to predict the CPI for 15 DR targets using random forest (RF), k‐nearest neighbours (KNN), support vector machine (SVM), and neural network (NN) algorithms with MACCS, extended connectivity fingerprints (ECFP6) fingerprints, and protein descriptors. In order to facilitate discovery of the novel drugs and target identification using the 128 binary classifiers, a free web server (DRDB) was developed. Compound Danshen Dripping Pills (CDDP), composed of Salvia miltiorrhiza, Panax notoginseng, and borneol, is commonly used in the treatment of cardiovascular diseases. To explore the applicability of DRDB, the potential CPIs of CDDP in treatment of DR were investigated based on DRDB. In vitro experimental validation demonstrated that cryptotanshinone and protocatechuic acid, two key components of CDDP, are capable of targeting ICAM‐1 which is one of the key target of DR. We hope that this work can facilitate development of more effective clinical strategies for the treatment of DR.
- 1 November 2017
- Published by Elsevier in The American Journal of Pathology
- Vol. 187 (11) , A3-A5
Table of Contents
- 1 November 2017
- Published by Elsevier in The American Journal of Pathology
- Vol. 187 (11) , A3-A5
Table of Contents
- Open Access
- 6 August 2013
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 11 (1) , 175
A rare case of bilateral sequential spermatocytic seminoma
Spermatocytic seminoma (SS) is a rare testicular neoplasm characterized by a palpable, painless, slowly enlarging mass in the testis. Even more rare is a synchronous bilateral presentation. Only eight cases of bilateral SS have been reported in the literature, of which three cases were present with synchronous testis enlargement, and five were sequential. Here, we report an additional case of synchronous bilateral SS and present a comprehensive relevant literature review concerning clinical features, histopathology, and treatment.
- 6 August 2013
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 11 (1) , 175
Open AccessA rare case of bilateral sequential spermatocytic seminoma
Spermatocytic seminoma (SS) is a rare testicular neoplasm characterized by a palpable, painless, slowly enlarging mass in the testis. Even more rare is a synchronous bilateral presentation. Only eight cases of bilateral SS have been reported in the literature, of which three cases were present with synchronous testis enlargement, and five were sequential. Here, we report an additional case of synchronous bilateral SS and present a comprehensive relevant literature review concerning clinical features, histopathology, and treatment.